- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01234454
Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI
Risperidone Effects On Frontal And Temporal Cortical Function In Schizophrenia Patients Undergoing FMRI Cognitive Task Performance
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The general aim of this study was to determine the neuroanatomic basis for cognitive pathology in schizophrenia, as well as the effects of treatment with typical and atypical antipsychotics on clinical symptoms, neurocognition and brain function, as measured with function magnetic resonance imaging. Subjects underwent a randomized parallel group treatment trial that consisted of: a four-week Thiothixene treatment period, followed by randomization, two-weeks cross titration, and six-weeks of double blind treatment with Risperidone (RIS) or Olanzapine (OLZ). Twenty-three patients with schizophrenia or schizoaffective disorder and fifteen healthy control subjects were initially enrolled. Diagnosis was established with the SCID. Subjects were assessed at two time points, at baseline after four weeks of Thiothixene treatment and at follow up, after eight weeks of double-blind atypical antipsychotic treatment. Controls were assessed once. Symptom severity was assessed using the PANSS. Cognitive functions associated with frontal and temporal cortical regions were probed with a neurocognitive testing battery using standardized attention, executive function and working memory tasks. Frontal and temporal cortical function was assessed with fMRI during the performance of visual and auditory oddball tasks. The visual task oddball task consisted of identifying an infrequent square presented within a series of frequent squares. The auditory oddball task consisted of identifying an infrequent pitch-deviant target tone embedded within a series of frequent standard tones. Thirteen patients and eleven controls completed fMRI at baseline and follow-up.
The results indicated that patients treated with the typical neuroleptic Thiothixene showed significantly smaller extents of activations in superior temporal, anterior cingulate and thalamic regions as compared to control subjects during the auditory oddball task. Although treatment with atypical neuroleptics considerably reduced group differences in cortical activation between controls and patients, the current sample size proved to be insufficient to yield statistically significant group by time interactions. The percent signal change data was in the same direction, but proved to be less sensitive to group differences than the extent of activation. The group differences were not pronounced during the visual oddball task, but were in the same direction.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Unc Psychiatry
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion Criteria for Schizophrenia/Schizoaffective Subjects
- Men and women between ages of 18 to 60 inclusive, of any ethnic origin.
- Subjects must be right handed.
- DSM IV criteria for chronic schizophrenia or schizoaffective disorder.
- Good physical health as determined by complete physical examination, laboratory tests, and EKG
Inclusion Criteria for Healthy Control Subjects:
1. Fifteen individuals, matched to the patient subjects on the basis of age, gender, parental SES, handedness.
Exclusion Criteria:
Exclusion Criteria for Schizophrenia/Schizoaffective Subjects
- Previous poor response or adverse side effects to thiothixene, olanzapine or risperidone.
- Left handedness
- Epilepsy, HIV, or current myeloproliferative disorder
- Current severe major depression.
- Current or past history of Substance Dependence (except caffeine or nicotine)
- Criteria for active Substance Abuse within past 30 days
- Learning disability
- Mental Retardation
- Foreign metal objects or implants as determined by MRI safety questionnaires
- If judged unsuitable for the study based on other medical or psychiatric condition according to the PIs best clinical judgment.
- No depot neuroleptic within 60 days before the day of randomization.
- Women who are pregnant or breastfeeding, and/or unwilling to take a pregnancy test.
Exclusion Criteria for Healthy Control Subjects
1. History of psychiatric disorder or current medical illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Risperidone Treatment Group
A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene.
A six-week double blind active treatment period followed.
Target dose was 6mg/day or highest dose tolerated.
|
6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
Other Names:
|
EXPERIMENTAL: Olanzapine Treatment Group
A two-week cross-titration phase followed randomization when patients started treatment with Olanzapine in a double-blind manner and were tapered off Thiothixene.
A six-week double blind active treatment period followed.
Target dose 20mg/day (or the highest dose tolerated) for 8 weeks, following 4 weeks of baseline Thiothixene.
|
20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
Other Names:
|
NO_INTERVENTION: Thiothixene
Subjects were first stabilized on open-label Thiothixene for four weeks, target dose 25 mg per day.
Patients were then randomized to either Risperidone or Olanzapine treatment for 8 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Neurocognitive Assessment Procedure
Time Frame: Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
Composite score derived from the neurocognitive battery used in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia clinical trial and the Brief Assessment of Cognition in Schizophrenia (BACS).
|
Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
fMRI activation Tasks
Time Frame: Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
During MR imaging subjects performed one visual-auditory target detection task and one auditory oddball task.
Subjects completed runs consisting of 160 trials with a total duration of approximately 4 min.
During odd numbered runs, subjects performed a visual target detection task.
During even numbered runs, subjects performed an auditory target detection task.
|
Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Performance accuracy on Visual-auditory target detection task
Time Frame: Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
Per fMRI activation tasks.
For the visual task, subjects were asked to pay attention to a screen where two types of stimuli were displayed: 1) Standards were squares of varying size and color that comprised ~95% of trials 2) Targets were circles of varying zize and colors that were presented irriegularly on ~5% of trials.
The onsets of successive Targets were separated by a minimum of 15 seconds.
|
Baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
Performance accuracy on Auditory oddball target detection task
Time Frame: baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
Per fMRI activation tasks.
Subjects were asked to pay attention to attend to auditory stimuli presented at a rate of one per 500 msecs for each run.
Standards were 500 msec duration 440 Hz pure tones that were presented on ~95% of trials.
Frequency-deviant Target tones were 500msec duration 800 Hz pure tones presented irregularly on ~5% of trials.
The onsets of successive deviant tones were separated by a minimum of 15 seconds.
During both tasks subjects were instructed to press a button whenever a Target was presented.
No overt or covert response was required of Standards.
|
baseline, after four weeks of Thiothixine, then follow-up after 8 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: AYSENIL BELGER, University of North Carolina, Chapel Hill
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Olanzapine
- Risperidone
Other Study ID Numbers
- RIS-USA-242
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Risperidone
-
Rovi Pharmaceuticals LaboratoriesCompletedAcute SchizophreniaUnited States, Ukraine
-
Northwestern UniversityOrtho-McNeil Janssen Scientific Affairs, LLCCompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Rovi Pharmaceuticals LaboratoriesCompletedSchizophrenia | Schizoaffective DisorderSpain, South Africa, Russian Federation, Croatia
-
Zogenix, Inc.CompletedSchizophrenia | Schizoaffective DisorderUnited States
-
Zogenix, Inc.Completed
-
Janssen-Cilag S.p.A.CompletedSchizophrenia | Schizoaffective Disorder
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
Xijing HospitalUnknown
-
Hoffmann-La RocheCompleted
-
Janssen Korea, Ltd., KoreaCompleted